ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. The first prototypes of CRISPRChek will focus on HIV & SARS-CoV-2 detection and quantification and will offer an alternative to the current qPCR detection methodologies used in all molecular biology laboratories.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, expressed his confidence that the team of experts will face the exciting challenges posed by the CRISPR technology, which is usually used for therapy genic applications, and will lead to innovative assays with the potential to revolutionize the way molecular detection is currently carried-out.
ABL Diagnostics’ portfolio of genotyping-through-sequencing tests (DeepChek®) already covers a broad range of applications, including HIV (with CE-IVD marked target-specific assays covering all relevant genes used for drug resistance assessment like reverse transcriptase, protease, integrase and with disruptive Whole Genome Kits), SARS-CoV-2 (with a CE-IVD marked Whole Genome assay), Tuberculosis (with a CE-IVD marked multiplex assay targeting genes relevant for first line, second line and new-drugs resistance determination), viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets.
ABL Diagnostics commercializes its products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents.
Today’s announcement from ABL Diagnostics marks a major evolution of its research & development activities with the introduction of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. The first prototypes of CRISPRChek will focus on HIV & SARS-CoV-2 detection and quantification and will offer an attractive alternative to the current qPCR detection methodologies used in molecular biology laboratories.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, said: “CRISPR is a new technology coming with new challenges, but I’m confident that our team of experts will face these exciting challenges which will lead to innovative assays with the potential to revolution the way molecular detection is currently carried-out.”
ABL Diagnostics’ portfolio of genotyping-through-sequencing tests (DeepChek®) covers a broad range of applications, including HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets.
The company commercializes its products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents.
ABL Diagnostics is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics has announced the launch of a new line of PCR detection assays, CRISPRChek, using the disruptive CRISPR technology. The first prototypes of CRISPRChek will focus on HIV & SARS-CoV-2 detection and quantification and will be an attractive alternative to current qPCR detection methodologies used in all molecular biology laboratories.
Dr. Sofiane Mohamed, Head of Research and Development at ABL Diagnostics, expressed his confidence that their team of experts will face the exciting challenges posed by the CRISPR technology, which is usually used for therapy genic applications, and will lead to innovative assays with the potential to revolutionize the way molecular detection is currently carried-out.
The company’s portfolio of genotyping-through-sequencing tests (DeepChek®) covers a broad range of applications, including HIV, SARS-CoV-2, Tuberculosis, viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analyses and other viral and bacterial targets.
ABL Diagnostics commercializes its products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents. ABL Diagnostics is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.